A detailed history of Manufacturers Life Insurance Company, The transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 206,819 shares of DNLI stock, worth $5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
206,819
Previous 172,281 20.05%
Holding current value
$5 Million
Previous $4 Million 50.6%
% of portfolio
0.01%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$20.96 - $31.05 $723,916 - $1.07 Million
34,538 Added 20.05%
206,819 $6.02 Million
Q2 2024

Aug 14, 2024

BUY
$14.96 - $23.22 $346,548 - $537,891
23,165 Added 15.53%
172,281 $4 Million
Q1 2024

May 14, 2024

BUY
$15.83 - $23.35 $758,146 - $1.12 Million
47,893 Added 47.31%
149,116 $3.06 Million
Q4 2023

Feb 13, 2024

SELL
$16.2 - $23.18 $197,235 - $282,216
-12,175 Reduced 10.74%
101,223 $2.17 Million
Q3 2023

Nov 15, 2023

SELL
$20.63 - $30.17 $114,517 - $167,473
-5,551 Reduced 4.67%
113,398 $2.34 Million
Q2 2023

Aug 11, 2023

BUY
$23.37 - $32.96 $161,019 - $227,094
6,890 Added 6.15%
118,949 $3.51 Million
Q1 2023

May 15, 2023

BUY
$21.91 - $32.67 $68,446 - $102,061
3,124 Added 2.79%
115,183 $2.65 Million
Q4 2022

Aug 11, 2023

BUY
$26.28 - $33.92 $47,356 - $61,123
1,802 Added 1.63%
112,059 $3.12 Million
Q4 2022

Feb 13, 2023

BUY
$26.28 - $33.92 $47,356 - $61,123
1,802 Added 1.63%
112,059 $3.12 Million
Q3 2022

Aug 11, 2023

SELL
$25.97 - $38.53 $260,479 - $386,455
-10,030 Reduced 8.34%
110,257 $3.38 Million
Q3 2022

Nov 03, 2022

SELL
$25.97 - $38.53 $260,479 - $386,455
-10,030 Reduced 8.34%
110,257 $3.29 Million
Q2 2022

Aug 11, 2023

BUY
$20.88 - $35.19 $45,977 - $77,488
2,202 Added 1.86%
120,287 $3.54 Million
Q2 2022

Aug 15, 2022

BUY
$20.88 - $35.19 $45,977 - $77,488
2,202 Added 1.86%
120,287 $3.5 Million
Q1 2022

Aug 11, 2023

BUY
$29.0 - $47.27 $84,158 - $137,177
2,902 Added 2.52%
118,085 $3.8 Million
Q1 2022

May 20, 2022

BUY
$29.0 - $47.27 $2.08 Million - $3.38 Million
71,589 Added 153.97%
118,085 $3.82 Million
Q4 2021

Feb 16, 2022

SELL
$42.59 - $55.02 $18,697 - $24,153
-439 Reduced 0.94%
46,496 $2.09 Million
Q3 2021

Nov 12, 2021

SELL
$48.48 - $78.23 $213,215 - $344,055
-4,398 Reduced 8.57%
46,935 $2.37 Million
Q2 2021

Aug 12, 2021

BUY
$50.3 - $78.44 $768,936 - $1.2 Million
15,287 Added 42.41%
51,333 $4.03 Million
Q1 2021

May 03, 2021

SELL
$53.8 - $81.53 $119,328 - $180,833
-2,218 Reduced 5.8%
36,046 $2.06 Million
Q4 2020

Feb 12, 2021

BUY
$36.89 - $93.56 $41,206 - $104,506
1,117 Added 3.01%
38,264 $3.21 Million
Q3 2020

Nov 09, 2020

SELL
$23.13 - $38.84 $24,309 - $40,820
-1,051 Reduced 2.75%
37,147 $1.33 Million
Q2 2020

Aug 10, 2020

BUY
$16.01 - $28.82 $75,679 - $136,232
4,727 Added 14.12%
38,198 $905,000
Q1 2020

May 15, 2020

BUY
$14.2 - $27.98 $42,983 - $84,695
3,027 Added 9.94%
33,471 $586,000
Q4 2019

Feb 14, 2020

SELL
$14.4 - $19.99 $12,081 - $16,771
-839 Reduced 2.68%
30,444 $530,000
Q3 2019

Nov 12, 2019

SELL
$15.32 - $21.92 $674 - $964
-44 Reduced 0.14%
31,283 $496,000
Q2 2019

Aug 14, 2019

BUY
$18.5 - $28.14 $4,606 - $7,006
249 Added 0.8%
31,327 $650,000
Q1 2019

May 13, 2019

BUY
$17.99 - $24.65 $53,556 - $73,383
2,977 Added 10.59%
31,078 $722,000
Q4 2018

Feb 14, 2019

SELL
$13.88 - $21.75 $42,222 - $66,163
-3,042 Reduced 9.77%
28,101 $581,000
Q3 2018

Nov 14, 2018

BUY
$12.46 - $21.74 $193,117 - $336,948
15,499 Added 99.07%
31,143 $677,000
Q2 2018

Aug 14, 2018

BUY
$15.25 - $21.02 $17,979 - $24,782
1,179 Added 8.15%
15,644 $238,000
Q1 2018

May 15, 2018

BUY
$15.36 - $24.8 $222,182 - $358,732
14,465 New
14,465 $285,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.24B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.